Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia

NCT02274233 is registered in ClinicalTrials.gov with Sideris Pharmaceuticals as lead sponsor.

NCT NCT02274233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02274233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia
Lead sponsor
Sideris Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2014
Completion date
September 30, 2015
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia, iron overload